Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, open-label, multicenter study to evaluate the safety and anti-tumor efficacy of AZD4205 in subjects with peripheral T-cell lymphoma who had tumor remission after first-line systemic therapy

Next Previous
Trial Profile

A Phase II, open-label, multicenter study to evaluate the safety and anti-tumor efficacy of AZD4205 in subjects with peripheral T-cell lymphoma who had tumor remission after first-line systemic therapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golidocitinib (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Acronyms JACKPOT26
  • Sponsors Dizal Pharmaceutical

Most Recent Events

  • 15 May 2025 According to a Dizal Pharmaceutical media release, data from this trial will be presented at the 2025 European Hematology Association (EHA) Congress and the 18th International Conference on Malignant Lymphoma (ICML), upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, EHA Congress and ICML.
  • 19 Jul 2024 Status changed from planning to active, no longer recruiting.
  • 12 Dec 2023 Results (As of June 27, 2023, n=48) assessing antitumor efficacy and safety of golidocitinib as maintenance treatment after first-line therapy presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top